glp-1 news today november 2025 ISPOR 2025: Exploring reasons for discontinuation Mapping the effectiveness and risks

These gastrointestinal events were predominantly of minor to intermediate severity

Prescription medications are only provided after a consultation with a licensed healthcare provider if the provider determines that the prescription medication is appropriate for you

JCI Insight 7 , e160891 (2022)

Go EJ, et al

Data from clinical trials show A1C reductions of 12% when combining these agents, though individual responses vary based on baseline insulin secretion capacity, beta-cell function, and genetic factors influencing GLP-1R expression

Beyond their metabolic effects, GLP-1 RAs have demonstrated cardiovascular and renal benefits in large outcome trials, including reductions in major adverse cardiovascular events (MACE) and attenuation of albuminuria progression ( Table 1 , renal eligibility criteria across landmark GLP-1 RA cardiovascular and kidney outcome trials consistently excluded dialysis-dependent patients, resulting in a persistent lack of randomized evidence in this high-risk population